AROANG-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for Mixed Dyslipidemia. According to GlobalData, Phase II drugs for Mixed Dyslipidemia have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AROANG-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AROANG-3 is under development for the treatment of dyslipidemic patients including familial hypercholesterolemia including homozygous familial hypercholesterolemia and heterozygous familial hypercholesterolemia (heFH) , severe hypertriglyceridemia and mixed dyslipidemia. It is administered through subcutaneous route. The therapeutic candidate acts by targeting angiopoietin-like 3 protein (ANGPTL3). The drug candidate is developed based on targeted RNAi molecule (TRiM) platform.
Arrowhead Pharmaceuticals overview
Arrowhead Pharmaceuticals (Arrowhead), formerly Arrowhead Research, is a pharmaceutical company. It develops and markets medicinal products including ARO-AAT, JNJ-3989, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, ARO-Lung2, ARO-HSD, ARO-HIF2, AMG 890, ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3.The company develops pipeline drugs that are being developed to treat chronic hepatitis B infection for the treatment of liver disease, cardiovascular disease, hypertriglyceridemia, dyslipidemia, cystic fibrosis and and renal cell carcinoma. It also offers design of internal preclinical and clinical development programs to enable novel new therapies. The company has operations in California and Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.
For a complete picture of AROANG-3’s drug-specific PTSR and LoA scores, buy the report here.